Generalizable AI predicts immunotherapy outcomes across cancers and treatments
Wanxiang Shen / nature - Nature Medicine, Published online: 03 July 2026; doi:10.1038/s41591-026-04502-7COMPASS is a pan-cancer foundation model that predicts immunotherapy response, across cancer types and treatments, from bulk tumor transcriptomes.
AI Summary: Researchers unveiled a generalizable AI tool that predicts which patients will respond to immunotherapy across multiple cancer types and treatment regimens. By integrating diverse clinical and molecular data, the model helps stratify likely responders and could reduce exposure to costly, ineffective checkpoint therapy—promising smarter patient selection, faster trials, and fewer frustrated oncologists.
- Broader AI advances in oncology and immunotherapy research (4)
- COMPASS pan-cancer model predicts immunotherapy response (5)
- All Other Stories
Broader AI advances in oncology and immunotherapy research
COMPASS pan-cancer model predicts immunotherapy response
All Other Stories
Related Stories
ALTAIR trial probes ctDNA‑guided post‑adjuvant therapy in CRC / 28 days
Deep‑learning pathomics platform may predict immunotherapy response in lung cancer / 2 months
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 6 hrs
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 5 wks
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 5 wks
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 2 months
AI face photos may predict cancer survival years earlier / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try None, Trump Administration, Corporate Takeover, Eli Lilly and look for the RSS link.
StackHealth Time Machine